Medibact GuidesShop at Medibact

Stacking Module

Semaglutide Stacking Module

Semaglutide is one of only two compounds in this catalog where stacking is the wrong frame entirely. It is an approved prescription medicine with a boxed warning, and it is also the only compound here that is part of a combination under formal clinical development — which is a useful illustration of what it actually takes for a combination to acquire evidence.

Semaglutide Guide at MedibactSemaglutide calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking Semaglutide

  • Semaglutide is a GLP-1 receptor agonist and an approved medicine (Ozempic, Wegovy, Rybelsus). Its combinations are clinical decisions with documented interaction profiles.
  • Adding a second GLP-1 agonist or a dual incretin agonist duplicates GLP-1 signaling. Tirzepatide already contains GLP-1 activity, so pairing the two is redundant on that pathway while doubling the side-effect profile.
  • Delayed gastric emptying alters the absorption of oral medications taken alongside it — the mechanism behind the documented oral-contraceptive interaction for this drug class.
  • Cagrilintide plus semaglutide (CagriSema) is the single combination in this catalog evaluated in controlled trials, and it is being developed as one regulated product rather than as a stack.

Combinations in detail

CagriSema

Semaglutide + Cagrilintide
Why it is proposed
Amylin-receptor agonism and GLP-1 agonism are genuinely distinct appetite pathways, and the combination has been studied on that basis — Phase 3 data reported substantially larger weight reduction than semaglutide alone.
What is reported in practice
In trials, both are administered once weekly with independent titration. It is being developed as a single combined product, not assembled by the user.
Cautions specific to this combination
That this combination has evidence is precisely because it went through trials as a product. Assembling it from two research-market vials is not the same intervention, and the trial's monitoring context is absent.

Lean-mass preservation discussion

Semaglutide + BPC-157
Why it is proposed
Community reasoning holds that rapid weight loss includes lean mass, and that a repair compound might offset that. The mechanisms are unrelated, so it is not a class collision.
What is reported in practice
Reported as separate vials on separate schedules.
Cautions specific to this combination
There is no evidence that BPC-157 preserves lean mass in this or any context. Resistance training and protein intake are the interventions with actual evidence for that objective, and neither requires a peptide.

What to avoid, and why

  • Combining semaglutide with tirzepatide or another GLP-1 agonist — duplicate GLP-1 signaling with compounded gastrointestinal effects.
  • Applying research-peptide cycling conventions; the label describes continued treatment, and weight regain after discontinuation is documented.
  • Treating research-market material as equivalent to the pharmacy product when reasoning about a combination — the interaction profile belongs to the molecule, but the manufacturing and oversight do not.
  • This is an approved prescription medicine with a boxed warning and documented contraindications. Combining it with anything is a clinical decision, not a stacking choice — its interactions (notably hypoglycaemia risk with insulin or sulfonylureas, and altered absorption of oral medications through delayed gastric emptying) are characterised, not theoretical.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.